The establishment of the facility demonstrates the company's commitment to delivering differentiated solutions to gynecology and pediatrics challenges
Furthering cell therapy ambition across oncology and autoimmune diseases
US FDA approval based on NEURO-TTRansform Phase III results
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
Trinity has availed credit facility from Investec for Business for their working capital requirements of Rs. 31.5 crore
JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market
Employer-sponsored health insurance costs in India are expected to rise by 11% in 2024
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
Development services for gene and cell therapies is planned to begin first in 2025
Subscribe To Our Newsletter & Stay Updated
